Zydus Lifesciences is on analysts' radar. Analyst Sameer Pande noted that it was facing a resistance zone between ₹940 and ₹1,000, which had repeatedly stalled in recent sessions. He also observed that while the broader trend remains stable, the stock needs to decisively cross the ₹1,010 level to confirm a short-term uptrend.